Ad blocker interference detected!
Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers
Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.
Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|Complete androgen insensitivity syndrome|
|Classification and external resources|
AIS results when the function of the androgen receptor (AR) is impaired. The AR protein (pictured) mediates the effects of androgens in the human body.
Complete androgen insensitivity syndrome (CAIS) is a condition that results in the complete inability of the cell to respond to androgens. The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does not significantly impair female genital or sexual development. As such, the insensitivity to androgens is only clinically significant when it occurs in genetic males (i.e. individuals with a Y chromosome, or more specifically, an SRY gene). All affected individuals are phenotypically female; they develop a normal female habitus, despite the presence of a Y chromosome.
CAIS is one of three types of androgen insensitivity syndrome, which is divided into three categories that are differentiated by the degree of genital masculinization: complete androgen insensitivity syndrome (CAIS) is indicated when the external genitalia is that of a normal female, mild androgen insensitivity syndrome (MAIS) is indicated when the external genitalia is that of a normal male, and partial androgen insensitivity syndrome (PAIS) is indicated when the external genitalia is partially, but not fully masculinized.
Signs and symptomsEdit
Individuals with complete androgen insensitivity syndrome (grades 6 and 7 on the Quigley scale) are born phenotypically female, without any signs of genital masculinization, despite having a 46,XY karyotype. Symptoms of CAIS do not appear until puberty, which may be slightly delayed, but is otherwise normal except for absent menses and diminished or absent secondary terminal hair. Axillary hair (i.e. armpit hair) fails to develop in one third of all cases. External genitalia is normal, although the labia and clitoris are sometimes underdeveloped. The vaginal depth is widely variable, but is typically shorter than unaffected women; one study of eight women with CAIS measured the average vaginal depth to be 5.9 cm  (vs. 11.1 ± 1.0 cm for unaffected women ). In some extreme cases, the vagina has been reported to be aplastic (resembling a "dimple"), though the exact incidence of this is unknown.
The gonads in these women are not ovaries, but instead, are testes; during the embryonic stage of development, testes form in an androgen-independent process that occurs due to the influence of the SRY gene on the Y chromosome. They may be located intra-abdominally, at the internal inguinal ring, or may herniate into the labia majora, often leading to the discovery of the condition. Testes in affected women have been found to be atrophic upon gonadectomy. Testosterone produced by the testes cannot be directly used due to the mutant androgen receptor that characterizes CAIS; instead, it is aromatized into estrogen, which effectively feminizes the body and accounts for the normal female phenotype observed in CAIS.
Immature sperm cells in the testes are arrested at an early stage and do not mature, since sensitivity to androgens is required in order for spermatogenesis to complete. Germ cell malignancy risk, once thought to be relatively high, is now thought to be approximately 2%. Wolffian structures (the epididymides, vasa deferentia, and seminal vesicles) are typically absent, but will develop at least partially in approximately 30% of cases, depending on which mutation is causing the CAIS. The prostate, like the external male genitalia, cannot masculinize in the absence of androgen receptor function, and thus remains in the female form.
The Müllerian system (the fallopian tubes, uterus, and upper portion of the vagina) typically regresses due to the presence of anti-Müllerian hormone originating from the Sertoli cells of the testes. These women are thus born without fallopian tubes, a cervix, or a uterus, and the vagina ends "blindly" in a pouch. Müllerian regression does not fully complete in approximately one third of all cases, resulting in Müllerian "remnants". Although rare, a few cases of women with CAIS and fully developed Müllerian structures have been reported. In one exceptional case, a 22 year old with CAIS was found to have a normal cervix, uterus, and fallopian tubes. In an unrelated case, a fully developed uterus was found in a 22 year old adult with CAIS.
Other subtle differences that have been reported include slightly longer limbs and larger hands and feet due to a proportionally greater stature than unaffected women, larger teeth, minimal or no acne, well developed breasts, and a greater incidence of meibomian gland dysfunction (i.e. dry eye syndromes and light sensitivity).
CAIS is associated with a decreased bone mineral density. Some have hypothesized that the decreased bone mineral density observed in women with CAIS is related to the timing of gonadectomy and inadequate estrogen supplementation. However, recent studies show that bone mineral density is similar whether gonadectomy occurs before or after puberty, and is decreased despite estrogen supplementation, leading some to hypothesize that the deficiency is directly attributable to the role of androgens in bone mineralization.
CAIS is also associated with an increased risk for gonadal tumors (e.g. germ cell malignancy) in adulthood if gonadectomy is not performed. The risk of malignant germ cell tumors in women with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. The incidence of gonadal tumors in childhood is thought to be relatively low; a recent review of the medical literature  found that only three cases of malignant germ cell tumors in prepubescent girls have been reported in association with CAIS in the last 100 years. Some have estimated the incidence of germ cell malignancy to be as low as 0.8% before puberty.
At least one study indicates that individuals with an intersex condition may be more prone to psychological difficulties, due at least in part to parental attitudes and behaviors, and concludes that preventative long-term psychological counseling for parents as well as for affected individuals should be initiated at the time of diagnosis.
Lifespan is not thought to be affected by AIS.
- Main article: Androgen insensitivity syndrome#Diagnosis
CAIS can only be diagnosed in normal phenotypic females. It is not usually suspected unless the menses fail to develop at puberty, or an inguinal hernia presents during premenarche. As many as 1-2% of prepubertal girls that present with an inguinal hernia will also have CAIS.
A diagnosis of CAIS or Swyer syndrome can be made in utero by comparing a karyotype obtained by amniocentesis with the external genitalia of the fetus during a prenatal ultrasound. Many infants with CAIS do not experience the normal, spontaneous neonatal testosterone surge, a fact which can be diagnostically exploited by obtaining baseline luteinizing hormone and testosterone measurements, followed by a human chorionic gonadotropin (hGC) stimulation test.
The main differentials for CAIS are complete gonadal dysgenesis (Swyer syndrome) and Müllerian agenesis (Mayer-Rokitansky-Kuster-Hauser syndrome or MRKH). Both CAIS and Swyer syndrome are associated with a 46,XY karyotype, whereas MRKH is not; MRKH can thus be ruled out by checking for the presence of a Y chromosome, which can be done either by fluorescence in situ hybridization (FISH) analysis or on full karyotype. Swyer syndrome is distinguished by poor breast development and shorter stature. The diagnosis of CAIS is confirmed when AR gene sequencing reveals a mutation, although up to 5% of individuals with CAIS do not have an AR mutation.
Up until the 1990s, a CAIS diagnosis was often hidden from the affected individual and / or family. It is current practice to disclose the genotype at the time of diagnosis, particularly when the affected girl is at least of adolescent age. If the affected individual is a child or infant, it is generally up to the parents, often in conjunction with a psychologist, to decide when to disclose the diagnosis.
Management of AIS is currently limited to symptomatic management; methods to correct a malfunctioning androgen receptor protein that result from an AR gene mutation are not currently available. Areas of management include sex assignment, genitoplasty, gonadectomy in relation to tumor risk, hormone replacement therapy, and genetic and psychological counseling.
Individuals with CAIS are raised as females. They are born phenotypically female and almost always have a heterosexual female gender identity; the incidence of homosexuality in women with CAIS is thought to be less than unaffected women. However, at least two case studies have reported male gender identity in individuals with CAIS.
Most cases of vaginal hypoplasia associated with CAIS can be corrected using non-surgical pressure dilation methods. The elastic nature of vaginal tissue, as demonstrated by its ability to accommodate the differences in size between a tampon, a penis, and a baby's head, make dilation possible even in cases when the vaginal depth is significantly compromised. Treatment compliance is thought to be critical to achieve satisfactory results. Dilation can also be achieved via the Vecchietti procedure, which stretches vaginal tissues into a functional vagina using a traction device that is anchored to the abdominal wall, subperitoneal sutures, and a mold that is placed against the vaginal dimple. Vaginal stretching occurs by increasing the tension on the sutures, which is performed daily. The non-operative pressure dilation method is currently recommended as the first choice, since it is non-invasive, and highly successful. Vaginal dilation should not be performed before puberty.
While it is recommended that women with CAIS eventually undergo gonadectomy to mitigate cancer risk, there are differing opinions regarding early versus late gonadectomy. The risk of malignant germ cell tumors in women with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. However, only three cases of malignant germ cell tumors in prepubescent girls with CAIS have been reported in the last 100 years. The youngest of these girls was 14 years old. If gonadectomy is performed early, then puberty must be artificially induced using gradually increasing doses of estrogen. If gonadectomy is performed late, then puberty will occur on its own, due to the aromatization of testosterone into estrogen. Some choose to perform gonadectomy if and when inguinal hernia presents. Postoperative estrogen replacement therapy is critical to minimize bone mineral density deficiencies later in life.
Some have hypothesized that supraphysiological levels of estrogen may reduce the diminished bone mineral density associated with CAIS. Data has been published that suggests affected women who were not compliant with estrogen replacement therapy, or who had a lapse in estrogen replacement, experienced a more significant loss of bone mineral density. Progestin replacement therapy is seldom initiated, due to the absence of a uterus. Androgen replacement has been reported to increase a sense of well-being in gonadectomized women with CAIS, although the mechanism by which this benefit is achieved is not well understood.
It is no longer common practice to hide a diagnosis of CAIS from the affected individual or her family. Parents of children with CAIS need considerable support in planning and implementing disclosure for their child once the diagnosis has been established. For parents with young children, information disclosure is an ongoing, collaborative process requiring an individualized approach that evolves in concordance with the child's cognitive and psychological development. In all cases, the assistance of a psychologist experienced in the subject is recommended.
Many surgical procedures have been developed to create a neovagina, as none of them is ideal. Surgical intervention should only be considered after non-surgical pressure dilation methods have failed to produce a satisfactory result. Neovaginoplasty can be performed using skin grafts, a segment of bowel, ileum, peritoneum, Interceed, buccal mucosa, amnion, or dura mater. Success of such methods should be determined by sexual function, and not just by vaginal length, as has been done in the past. Ileal or cecal segments may be problematic because of a shorter mesentery, which may produce tension on the neovagina, leading to stenosis. The sigmoid neovagina is thought to be self-lubricating, without the excess mucus production associated with segments of small bowel. Vaginoplasty may create scarring at the introitus (the vaginal opening), which requires additional surgery to correct. Vaginal dilators are required postoperatively to prevent vaginal stenosis from scarring. Other complications include bladder and bowel injuries. Yearly exams are required as neovaginoplasty carries a risk of carcinoma, although carcinoma of the neovagina is uncommon. Neither neovaginoplasty nor vaginal dilation should be performed before puberty.
Challenges presented to people affected by this condition include: psychologically coming to terms with the condition, difficulties with sexual function, infertility. Long-term studies indicate that with appropriate medical and psychological treatment, women with CAIS can be satisfied with their sexual function and psychosexual development. CAIS women can lead active lives and expect a normal lifespan.
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 Hughes IA, Deeb A (December 2006). Androgen resistance. Best Pract. Res. Clin. Endocrinol. Metab. 20 (4): 577–98.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A (2008). Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens) 7 (3): 217–29.
- ↑ 3.0 3.1 Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (June 1995). Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16 (3): 271–321.
- ↑ 4.0 4.1 Giwercman YL, Nordenskjöld A, Ritzén EM, Nilsson KO, Ivarsson SA, Grandell U, Wedell A (June 2002). An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity. J. Clin. Endocrinol. Metab. 87 (6): 2623–8.
- ↑ 5.0 5.1 5.2 Zuccarello D, Ferlin A, Vinanzi C, Prana E, Garolla A, Callewaert L, Claessens F, Brinkmann AO, Foresta C (April 2008). Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin. Endocrinol. (Oxf) 68 (4): 580–8.
- ↑ 6.0 6.1 Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D, Cazzadore C, Foresta C (November 2006). Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. Clin. Endocrinol. (Oxf) 65 (5): 606–10.
- ↑ 7.0 7.1 7.2 Stouffs K, Tournaye H, Liebaers I, Lissens W (2009). Male infertility and the involvement of the X chromosome. Hum. Reprod. Update 15 (6): 623–37.
- ↑ Giwercman YL, Nikoshkov A, Byström B, Pousette A, Arver S, Wedell A (June 2001). A novel mutation (N233K) in the transactivating domain and the N756S mutation in the ligand binding domain of the androgen receptor gene are associated with male infertility. Clin. Endocrinol. (Oxf) 54 (6): 827–34.
- ↑ Lund A, Juvonen V, Lähdetie J, Aittomäki K, Tapanainen JS, Savontaus ML (June 2003). A novel sequence variation in the transactivation regulating domain of the androgen receptor in two infertile Finnish men. Fertil. Steril. 79 Suppl 3: 1647–8.
- ↑ Ozülker T, Ozpaçaci T, Ozülker F, Ozekici U, Bilgiç R, Mert M (January 2010). Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome. Ann Nucl Med 24 (1): 35–9.
- ↑ Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK (November 2007). Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis. J. Clin. Endocrinol. Metab. 92 (11): 4319–26.
- ↑ Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R (November 2005). Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients. J. Clin. Endocrinol. Metab. 90 (11): 6162–9.
- ↑ Gottlieb B, Lombroso R, Beitel LK, Trifiro MA (January 2005). Molecular pathology of the androgen receptor in male (in)fertility. Reprod. Biomed. Online 10 (1): 42–8.
- ↑ Ahmed SF, Cheng A, Hughes IA (April 1999). Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome. Arch. Dis. Child. 80 (4): 324–9.
- ↑ Jirásek JE, Simpson JL (1976). Disorders of sexual differentiation: etiology and clinical delineation, Boston: Academic Press.
- ↑ Gilbert SF (2000). Developmental biology, Sunderland, Mass: Sinauer Associates.
- ↑ 17.0 17.1 17.2 17.3 17.4 17.5 17.6 17.7 Oakes MB, Eyvazzadeh AD, Quint E, Smith YR (December 2008). Complete androgen insensitivity syndrome--a review. J Pediatr Adolesc Gynecol 21 (6): 305–10.
- ↑ 18.0 18.1 18.2 18.3 18.4 18.5 Nichols JL, Bieber EJ, Gell JS. Case of sisters with complete androgen insensitivity syndrome and discordant Müllerian remnants. Fertil Steril. 2009;91:932e15-e18.
- ↑ Melo KF, Mendonca BB, Billerbeck AE, Costa EM, Inácio M, Silva FA, Leal AM, Latronico AC, Arnhold IJ (July 2003). Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J. Clin. Endocrinol. Metab. 88 (7): 3241–50.
- ↑ 20.0 20.1 20.2 Minto CL, Liao KL, Conway GS, Creighton SM (July 2003). Sexual function in women with complete androgen insensitivity syndrome. Fertil. Steril. 80 (1): 157–64.
- ↑ Sinnecker GH, Hiort O, Nitsche EM, Holterhus PM, Kruse K (January 1997). Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur. J. Pediatr. 156 (1): 7–14.
- ↑ 22.0 22.1 22.2 22.3 22.4 22.5 22.6 Ismail-Pratt IS, Bikoo M, Liao LM, Conway GS, Creighton SM (July 2007). Normalization of the vagina by dilator treatment alone in Complete Androgen Insensitivity Syndrome and Mayer-Rokitansky-Kuster-Hauser Syndrome. Hum. Reprod. 22 (7): 2020–4.
- ↑ Weber AM, Walters MD, Schover LR, Mitchinson A (December 1995). Vaginal anatomy and sexual function. Obstet Gynecol 86 (6): 946–9.
- ↑ 24.00 24.01 24.02 24.03 24.04 24.05 24.06 24.07 24.08 24.09 24.10 24.11 24.12 24.13 24.14 24.15 24.16 Quint EH, McCarthy JD, Smith YR (March 2010). Vaginal surgery for congenital anomalies. Clin Obstet Gynecol 53 (1): 115–24.
- ↑ Achermann JC, Jameson JL (2006). "Disorders of sexual differentiation" Hauser SL, Kasper DL, Fauci AS, Braunwald E, Longo DL Harrison's endocrinology, 161–172, New York: McGraw-Hill Medical Pub. Division.
- ↑ Simpson JL, Rebar RW (2002). Hung, Wellington; Becker, Kenneth L.; Bilezikian, John P.; William J Bremner Principles and Practice of Endocrinology and Metabolism, 852–885, Hagerstwon, MD: Lippincott Williams & Wilkins.
- ↑ Decaestecker K, Philibert P, De Baere E, Hoebeke P, Kaufman JM, Sultan C, T'Sjoen G (May 2008). A novel mutation c.118delA in exon 1 of the androgen receptor gene resulting in complete androgen insensitivity syndrome within a large family. Fertil. Steril. 89 (5): 1260.e3–7.
- ↑ Morris JM (June 1953). The syndrome of testicular feminization in male pseudohermaphrodites. Am. J. Obstet. Gynecol. 65 (6): 1192–1211.
- ↑ Müller J (October 1984). Morphometry and histology of gonads from twelve children and adolescents with the androgen insensitivity (testicular feminization) syndrome. J. Clin. Endocrinol. Metab. 59 (4): 785–9.
- ↑ Boehmer AL, Brinkmann O, Brüggenwirth H, van Assendelft C, Otten BJ, Verleun-Mooijman MC, Niermeijer MF, Brunner HG, Rouwé CW, Waelkens JJ, Oostdijk W, Kleijer WJ, van der Kwast TH, de Vroede MA, Drop SL (September 2001). Genotype versus phenotype in families with androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 86 (9): 4151–60.
- ↑ Johnston DS, Russell LD, Friel PJ, Griswold MD (June 2001). Murine germ cells do not require functional androgen receptors to complete spermatogenesis following spermatogonial stem cell transplantation. Endocrinology 142 (6): 2405–8.
- ↑ Yong EL, Loy CJ, Sim KS (2003). Androgen receptor gene and male infertility. Hum. Reprod. Update 9 (1): 1–7.
- ↑ 33.0 33.1 33.2 33.3 Hughes IA, Houk C, Ahmed SF, Lee PA (July 2006). Consensus statement on management of intersex disorders. Arch. Dis. Child. 91 (7): 554–63.
- ↑ Hannema SE, Scott IS, Hodapp J, Martin H, Coleman N, Schwabe JW, Hughes IA (November 2004). Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 89 (11): 5815–22.
- ↑ Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B (1999). Regulation of androgen action. Vitam. Horm. 55: 309–52.
- ↑ Kokontis JM, Liao S (1999). Molecular action of androgen in the normal and neoplastic prostate. Vitam. Horm. 55: 219–307.
- ↑ 37.0 37.1 Rajender S, Gupta NJ, Chakrabarty B, Singh L, Thangaraj K (March 2009). Ala 586 Asp mutation in androgen receptor disrupts transactivation function without affecting androgen binding. Fertil. Steril. 91 (3): 933.e23–8.
- ↑ Chen CP, Chen SR, Wang TY, Wang W, Hwu YM (July 1999). A frame shift mutation in the DNA-binding domain of the androgen receptor gene associated with complete androgen insensitivity, persistent müllerian structures, and germ cell tumors in dysgenetic gonads. Fertil. Steril. 72 (1): 170–3.
- ↑ Papadimitriou DT, Linglart A, Morel Y, Chaussain JL (2006). Puberty in subjects with complete androgen insensitivity syndrome. Horm. Res. 65 (3): 126–31.
- ↑ 40.0 40.1 40.2 Wisniewski AB, Migeon CJ, Meyer-Bahlburg HFL, Gearhart JP, Berkovitz GD, Brown TR, Money J. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab. 2000;85;2664-2669.
- ↑ Varrela J, Alvesalo L, Vinkka H (1984). Body size and shape in 46,XY females with complete testicular feminization. Ann. Hum. Biol. 11 (4): 291–301.
- ↑ Alvesalo L, Varrela J (September 1980). Permanent tooth sizes in 46,XY females. Am. J. Hum. Genet. 32 (5): 736–42.
- ↑ Pietilä K, Grön M, Alvesalo L (August 1997). The craniofacial complex in karyotype 46,XY females. Eur J Orthod 19 (4): 383–9.
- ↑ Sultan C, Lumbroso S, Paris F, Jeandel C, Terouanne B, Belon C, Audran F, Poujol N, Georget V, Gobinet J, Jalaguier S, Auzou G, Nicolas JC (August 2002). Disorders of androgen action. Semin. Reprod. Med. 20 (3): 217–28.
- ↑ Zachmann M, Prader A, Sobel EH, Crigler JF, Ritzén EM, Atarés M, Ferrandez A (May 1986). Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J. Pediatr. 108 (5 Pt 1): 694–7.
- ↑ Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA (August 2003). Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?. Cornea 22 (6): 516–21.
- ↑ Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, Zhang H, Wang JC, Tao S, Liu X, Luo Z (January 2002). Male fertility is compatible with an Arg(840)Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome. J. Clin. Endocrinol. Metab. 87 (1): 347–51.
- ↑ Menakaya UA, Aligbe J, Iribhogbe P, Agoreyo F, Okonofua FE (May 2005). Complete androgen insensitivity syndrome with persistent Mullerian derivatives: a case report. J Obstet Gynaecol 25 (4): 403–5.
- ↑ Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, Wedell A, Skakkebaek NE (June 2000). Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene. J. Clin. Endocrinol. Metab. 85 (6): 2253–9.
- ↑ 50.0 50.1 Danilovic DL, Correa PH, Costa EM, Melo KF, Mendonca BB, Arnhold IJ (March 2007). Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. Osteoporos Int 18 (3): 369–74.
- ↑ 51.0 51.1 51.2 Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J (August 2006). Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J. Clin. Endocrinol. Metab. 91 (8): 3017–23.
- ↑ 52.0 52.1 52.2 52.3 52.4 Marcus R, Leary D, Schneider DL, Shane E, Favus M, Quigley CA (March 2000). The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 85 (3): 1032–7.
- ↑ 53.0 53.1 Bertelloni S, Baroncelli GI, Federico G, Cappa M, Lala R, Saggese G (1998). Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm. Res. 50 (6): 309–14.
- ↑ 54.0 54.1 54.2 Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS (December 1995). Osteopenia as a feature of the androgen insensitivity syndrome. Clin. Endocrinol. (Oxf) 43 (6): 671–5.
- ↑ Muñoz-Torres M, Jódar E, Quesada M, Escobar-Jiménez F (August 1995). Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif. Tissue Int. 57 (2): 94–6.
- ↑ 56.0 56.1 56.2 Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebaek NE, Coleman N, Hughes IA (March 2006). Testicular development in the complete androgen insensitivity syndrome. J. Pathol. 208 (4): 518–27.
- ↑ Rutgers JL, Scully RE (1991). The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases. Int. J. Gynecol. Pathol. 10 (2): 126–44.
- ↑ 58.0 58.1 58.2 Manuel M, Katayama PK, Jones HW (February 1976). The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am. J. Obstet. Gynecol. 124 (3): 293–300.
- ↑ Slijper FM, Drop SL, Molenaar JC, de Muinck Keizer-Schrama SM (April 1998). Long-term psychological evaluation of intersex children. Arch Sex Behav 27 (2): 125–44.
- ↑ Borisa AD, Puri Y, Wakade V, Alagappan C, Agarkhedkar N. Complete Androgen Insensitivity Syndrome Presenting as Bilateral Inguinal Hernia. Bombay Hosp J. 2006;48:668:673.
- ↑ Michailidis GD, Papageorgiou P, Morris RW, Economides DL (July 2003). The use of three-dimensional ultrasound for fetal gender determination in the first trimester. Br J Radiol 76 (907): 448–51.
- ↑ 62.0 62.1 Kulshreshtha B, Philibert P, Eunice M, Khandelwal SK, Mehta M, Audran F, Paris F, Sultan C, Ammini AC (December 2009). Apparent male gender identity in a patient with complete androgen insensitivity syndrome. Arch Sex Behav 38 (6): 873–5.
- ↑ Money J, Schwartz M, Lewis VG (1984). Adult erotosexual status and fetal hormonal masculinization and demasculinization: 46,XX congenital virilizing adrenal hyperplasia and 46,XY androgen-insensitivity syndrome compared. Psychoneuroendocrinology 9 (4): 405–14.
- ↑ Tsjoen G, De Cuypere G, Monstrey S, Hoebeke P, Freedman FK, Appari M, Holterhus PM, Van Borsel J, Cools M (April 2010). Male gender identity in complete androgen insensitivity syndrome. Arch Sex Behav. 40 (3): 635–638.
- ↑ Grover, S. Stretch Yourself. Alias 1996;1:76.
- ↑ Hurt WG, Bodurtha JN, McCall JB, Ali MM (September 1989). Seminoma in pubertal patient with androgen insensitivity syndrome. Am. J. Obstet. Gynecol. 161 (3): 530–1.
- ↑ Motoyama S, Laoag-Fernandez JB, Mochizuki S, Yamabe S, Maruo T (May 2003). Vaginoplasty with Interceed absorbable adhesion barrier for complete squamous epithelialization in vaginal agenesis. Am. J. Obstet. Gynecol. 188 (5): 1260–4.
- ↑ Jackson ND, Rosenblatt PL (December 1994). Use of Interceed Absorbable Adhesion Barrier for vaginoplasty. Obstet Gynecol 84 (6): 1048–50.
- ↑ 69.0 69.1 Steiner E, Woernle F, Kuhn W, Beckmann K, Schmidt M, Pilch H, Knapstein PG (January 2002). Carcinoma of the neovagina: case report and review of the literature. Gynecol. Oncol. 84 (1): 171–5.
- ↑ 70.0 70.1 70.2 70.3 70.4 Breech LL (2008). "Complications of vaginoplasty and clitoroplasty" Teich S, Caniano DA Reoperative pediatric surgery, 499–514, Totowa, N.J: Humana.
- GeneTests at NIH/UW androgen
- An Australian parent/patient booklet on CAIS
- The Secret of My Sex news article
- Women With Male DNA All Female news article at ABCnews.com
- Patient groups
- AIS Support Group AISSG (UK and International)
- AIS-DSD Support Group for Women & Families (US)
- AIS Support Group (Australasia)
- Intersex Support Forums (US and International)
Endocrine pathology of psychological interest (E00-35)
thyroid Hypothyroidism (Iodine deficiency, Cretinism, Congenital hypothyroidism, Goitre) - Hyperthyroidism (Graves-Basedow disease, Toxic multinodular goitre) - Thyroiditis (De Quervain's thyroiditis, Hashimoto's thyroiditis)
Sex linkage: X-linked recessive disorders
|No primary system|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|